AI Article Synopsis
- Reactive arthritis linked to Clostridium difficile infection is rare but has been documented in two cases involving a 40-year-old woman and a 47-year-old man.
- A review of literature from 1976 to 2016 identified a total of 54 cases, indicating that this condition often affects younger individuals and can involve multiple joints, typically improving with or without treatment.
- As C. difficile infections become more common, medical professionals should include reactive arthritis in their differential diagnosis when evaluating patients with bacterial infections.
Article Abstract
Introduction: Reactive arthritis due to Clostridium difficile infection is uncommon.
Case Reports: We report two cases of reactive arthritis associated with C. difficile infection that occurred in a 40-year-old woman and a 47-year-old man. The literature review between 1976 (date of first reported case) and 2016 retrieved 54 observations (including our two cases). Reactive arthritis occurs most frequently in young subjects after a variable time frame according to C. difficile infection, involving one or several articulations. The issue is generally favourable with or without anti-inflammatory treatment.
Conclusion: The increasing incidence of C. difficile infection makes more likely the occurrence of this related reactive arthritis. Therefore physicians should consider it in differential diagnosis of bacterial infections capable of causing reactive arthritis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.revmed.2016.12.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Efficacy and Adverse Events of Low-Dose Intravesical BCG Therapy for Non-Muscle-Invasive Bladder Cancer].
Hinyokika Kiyo
December 2024
The Department of Urology, Morinomiya Hospital.
We examined the efficacy and adverse effects of low-dose intravesical Bacillus Calmette-Guérin (BCG) therapy in patients with non-muscle-invasive bladder cancer. Patients who underwent intravesical BCG therapy (n＝176 ; 198 courses) at our hospital between April 2012 and December 2022 were enrolled. After assigning patients to either the low-dose or regular-dose (40 or 80 mg of BCG Tokyo 172 strain) groups, treatment efficacy and incidence of adverse events were compared.
View Article and Find Full Text PDFPrevalence and Associated Factors of Sarcopenia in Thai Rheumatoid Arthritis Patients: A Cross-Sectional Study.
J Clin Rheumatol
January 2025
From the Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Background/objectives: Sarcopenia associates with poor health-related quality of life (HRQoL). This study aimed to determine prevalence and factors associated with sarcopenia in rheumatoid arthritis (RA) patients. The HRQoL between RA patients with and without sarcopenia also was compared.
View Article and Find Full Text PDFReal-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis.
Rheumatol Ther
January 2025
OPAL Rheumatology Ltd, Sydney, NSW, Australia.
Introduction: This study sought to describe treatment patterns, persistence, and effectiveness of upadacitinib (UPA) alone and compared to other Janus kinase inhibitors (JAKis) or tumor necrosis factor inhibitors (TNFis) in patients with rheumatoid arthritis (RA).
Methods: This retrospective, non-interventional study used the OPAL dataset, derived from electronic medical records. Patients initiated UPA (N = 2624), other JAKis (baricitinib and tofacitinib [N = 925]), or TNFis (adalimumab, etanercept, certolizumab, golimumab, infliximab [N = 3540]) between May 2020 and March 2023.
Robust proteome profiling of cysteine-reactive fragments using label-free chemoproteomics.
Nat Commun
January 2025
Crick-GSK Biomedical LinkLabs, GSK, Gunnels Wood Road, Stevenage, Hertfordshire, UK.
Identifying pharmacological probes for human proteins represents a key opportunity to accelerate the discovery of new therapeutics. High-content screening approaches to expand the ligandable proteome offer the potential to expedite the discovery of novel chemical probes to study protein function. Screening libraries of reactive fragments by chemoproteomics offers a compelling approach to ligand discovery, however, optimising sample throughput, proteomic depth, and data reproducibility remains a key challenge.
View Article and Find Full Text PDFA mitochondria-targeted NIR fluorescence/photoacoustic dual-modality probe for highly sensitive and selective imaging of HClO in vivo.
Spectrochim Acta A Mol Biomol Spectrosc
December 2024
Department of Research & Clinical Laboratory, The Fifth Affiliated Hospital of Guangxi Medical University, The First People's Hospital of Nanning, Nanning 530022, Guangxi, PR China. Electronic address:
Article Synopsis
- Hypochlorous acid (HClO) is a reactive oxygen species produced in mitochondria, and its high levels are associated with various diseases, making its detection crucial in medicine.
- A new dual-modality probe called MB-ClO has been developed, which uses near-infrared fluorescence (NIRF) and photoacoustic (PA) imaging techniques to accurately and sensitively detect HClO in biological systems.
- MB-ClO shows low toxicity and good water solubility, has a fast response time, and has been successfully tested in a mouse model of rheumatoid arthritis, highlighting its potential for biomedical applications.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!